Breast milk paclitaxel excretion following intravenous chemotherapy-a case report

British Journal of Cancer
Christopher G C A JacksonTak Hung

Abstract

Breast cancer can be diagnosed during pregnancy and in the peri-partum period, and the potential exposure of a foetus or neonate to chemotherapy is of concern to mothers and clinicians. Paclitaxel is a commonly used agent in breast cancer, but little is known about its excretion in breast milk. Breastfeeding during chemotherapy has been traditionally cautioned against due to the risk of neonatal exposure to chemotherapy agents, however, data are limited. We measured serum and breast milk concentrations of paclitaxel in a 33-year-old woman with an early breast cancer diagnosed during pregnancy and treated with weekly paclitaxel 80 mg/m2. We found breast milk paclitaxel levels drop below the minimum quantifiable dose at 72 h following chemotherapy, with a relative infant dose of 0.091%. Breast milk excretion of paclitaxel following a dose of 80 mg/m2 is negligible at 72 h, and this may be a safe time to recommence breastfeeding following exposure.

References

Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M M MalingréJ H Schellens
Sep 5, 2001·Pediatrics·UNKNOWN American Academy of Pediatrics Committee on Drugs
Apr 23, 2003·Advanced Drug Delivery Reviews·Shinya Ito, Amy Lee
Apr 23, 2003·Advanced Drug Delivery Reviews·Jane Alcorn, Patrick J McNamara
Oct 23, 2012·Journal of Human Lactation : Official Journal of International Lactation Consultant Association·Stephen J GriffinThomas W Hale
Oct 24, 2012·International Journal of Cancer. Journal International Du Cancer·Jeroen J M A HendrikxAlfred H Schinkel
Nov 6, 2012·Clinical Breast Cancer·Flora ZagouriChristos A Papadimitriou
Sep 12, 2013·Obstetrics and Gynecology Clinics of North America·Iris Krishna, Michael Lindsay
Mar 19, 2014·Anti-cancer Drugs·Vincent A de WegerJan H M Schellens
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E SenkusUNKNOWN ESMO Guidelines Committee
Apr 10, 2016·Clinical Pharmacology and Therapeutics·Philip O Anderson, Jason B Sauberan
Feb 10, 2017·Cognitive Research: Principles and Implications·Teresa A TreatRichard J Viken
May 12, 2018·Obstetrics and Gynecology Clinics of North America·Anna McCormick, Erika Peterson

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray
biopsy

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
Sanjay AuroraThomas W Hale
Breastfeeding Medicine : the Official Journal of the Academy of Breastfeeding Medicine
Maria E FierroThomas W Hale
© 2021 Meta ULC. All rights reserved